227 related articles for article (PubMed ID: 12449450)
1. Low-molecular weight heparin: treatment failure in a patient with primary antiphospholipid antibody syndrome.
Ahmed S; Karim A; Patel D; Siddiqui R; Mattana J
Am J Med Sci; 2002 Nov; 324(5):279-80. PubMed ID: 12449450
[TBL] [Abstract][Full Text] [Related]
2. Variability in the international normalised ratio (INR) in patients with antiphospholipid syndrome and positive lupus anticoagulant: should the INR targets be higher?
Baquero-Salamanca M; Téllez-Arévalo AM; Calderon-Ospina C
BMJ Case Rep; 2015 Apr; 2015():. PubMed ID: 25858939
[TBL] [Abstract][Full Text] [Related]
3. Treatment and monitoring of patients with antiphospholipid antibodies and thrombotic history (Hughes syndrome).
Cuadrado MJ
Curr Rheumatol Rep; 2002 Oct; 4(5):392-8. PubMed ID: 12217243
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of long-term low molecular weight heparin in patients with antiphospholipid syndrome.
Vargas-Hitos JA; Ateka-Barrutia O; Sangle S; Khamashta MA
Ann Rheum Dis; 2011 Sep; 70(9):1652-4. PubMed ID: 21628306
[TBL] [Abstract][Full Text] [Related]
5. Deep venous thrombosis and pulmonary embolism. Part 1. Initial treatment: usually a low-molecular-weight heparin.
Prescrire Int; 2013 Apr; 22(137):99-101, 103-4. PubMed ID: 23662321
[TBL] [Abstract][Full Text] [Related]
6. Simultaneous intrahepatic and subgaleal hemorrhage in antiphospholipid syndrome following anticoagulation therapy.
Park IC; Baek YH; Han SY; Lee SW; Chung WT; Lee SW; Kang SH; Cho DS
World J Gastroenterol; 2013 Oct; 19(38):6494-9. PubMed ID: 24151371
[TBL] [Abstract][Full Text] [Related]
7. Is a therapeutic anticoagulation window needed for delivery when using prophylactic low molecular weight heparin during pregnancy? A retrospective monocentric study.
Roueli A; Cesario E; Amsellem J; Agman A; Vauthier-Brouzes D; Nizard J
Eur J Obstet Gynecol Reprod Biol; 2017 Aug; 215():118-123. PubMed ID: 28618257
[TBL] [Abstract][Full Text] [Related]
8. Bleeding and recurrent thrombosis in definite antiphospholipid syndrome: analysis of a series of 66 patients treated with oral anticoagulation to a target international normalized ratio of 3.5.
Ruiz-Irastorza G; Khamashta MA; Hunt BJ; Escudero A; Cuadrado MJ; Hughes GR
Arch Intern Med; 2002 May; 162(10):1164-9. PubMed ID: 12020188
[TBL] [Abstract][Full Text] [Related]
9. The use of fondaparinux and rituximab for recurrent thrombotic events in antiphospholipid syndrome.
Sayar Z; Burke S; Mittal P; Cohen H
Lupus; 2022 Oct; 31(12):1485-1490. PubMed ID: 36074077
[TBL] [Abstract][Full Text] [Related]
10. Successful use of fondaparinux in a child with heparin-induced thrombocytopenia.
Tokgoz H; Caliskan U; Demir M
Blood Coagul Fibrinolysis; 2012 Dec; 23(8):769-71. PubMed ID: 22964766
[TBL] [Abstract][Full Text] [Related]
11. Current management of antiphospholipid syndrome-related thrombosis.
Puente D; Pombo G; Forastiero R
Expert Rev Cardiovasc Ther; 2009 Dec; 7(12):1551-8. PubMed ID: 19954317
[TBL] [Abstract][Full Text] [Related]
12. Venous thromboembolism in the ICU and reversal of bleeding on anticoagulants.
DeLoughery TG
Crit Care Clin; 2005 Jul; 21(3):497-512. PubMed ID: 15992670
[TBL] [Abstract][Full Text] [Related]
13. Prevention of venous thromboembolic disease following primary total knee arthroplasty. A randomized, multicenter, open-label, parallel-group comparison of enoxaparin and warfarin.
Fitzgerald RH; Spiro TE; Trowbridge AA; Gardiner GA; Whitsett TL; O'Connell MB; Ohar JA; Young TR;
J Bone Joint Surg Am; 2001 Jun; 83(6):900-6. PubMed ID: 11407799
[TBL] [Abstract][Full Text] [Related]
14. Recurrent venous thrombosis despite 'optimal anticoagulation therapy' for antiphospholipid syndrome--could new oral anticoagulants solve the problem?
Balaban M; Stanrić V; Rincić G; Ledinsky M; Grbac L; Stancić N; Tomasić H
Acta Clin Croat; 2010 Dec; 49(4):469-77. PubMed ID: 21830460
[TBL] [Abstract][Full Text] [Related]
15. Monitoring of anticoagulation in thrombotic antiphospholipid syndrome.
Cohen H; Efthymiou M; Devreese KMJ
J Thromb Haemost; 2021 Apr; 19(4):892-908. PubMed ID: 33325604
[TBL] [Abstract][Full Text] [Related]
16. [Antiphospholipid antibodies--risk factors for venous thromboembolism and arterial thrombosis].
Zawilska K
Pol Arch Med Wewn; 2007; 117 Suppl():41-5. PubMed ID: 18778019
[TBL] [Abstract][Full Text] [Related]
17. Deep Venous Thrombosis and Pulmonary Embolism: Current Therapy.
Wilbur J; Shian B
Am Fam Physician; 2017 Mar; 95(5):295-302. PubMed ID: 28290648
[TBL] [Abstract][Full Text] [Related]
18. [Treatment of antiphospholipid syndrome].
Páramo JA; García R; Rodríguez P; Panizo E; Lecumberri R
Rev Med Univ Navarra; 2007; 51(4):38-41. PubMed ID: 18303659
[TBL] [Abstract][Full Text] [Related]
19. [The optimal duration of anticoagulant treatment following pulmonary embolism].
Couturaud F
Rev Mal Respir; 2011 Dec; 28(10):1265-77. PubMed ID: 22152935
[TBL] [Abstract][Full Text] [Related]
20. Antiphospholipid syndrome in pregnancy.
Bick RL
Hematol Oncol Clin North Am; 2008 Feb; 22(1):107-20, vii. PubMed ID: 18207069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
